PGR and breast cancer: Despite considerable funding, investment and resource distribution into the investigation of miRNA as reliable and reproducible clinical biomarkers in breast cancer research and treatment, we are yet to undercover novel biomarkers which can rival the principal ER, PgR, and HER2 receptors to inform breast cancer diagnosis, prognosis and therapeutic strategies.